POSEIDA THERAPEUTICS INC (PSTX) Stock Price, Quote, News and Overview
NASDAQ:PSTX - Nasdaq - US73730P1084 - Common Stock - Currency: USD
PSTX Quote, Performance and Key Statistics
POSEIDA THERAPEUTICS INC
NASDAQ:PSTX (1/7/2025, 8:07:14 PM)
After market: 9.54 +0.04 (+0.42%)9.5
-0.06 (-0.63%)
The current stock price of PSTX is 9.5 USD. In the past month the price increased by 1.5%. In the past year, price increased by 211.48%.
PSTX Latest News and Analysis
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PWOD, RVNC, B, PSTX on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, ZUO, PSTX on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, AVTE, GATO on Behalf of Shareholders
PSTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.07 | 341.06B | ||
| AMGN | AMGEN INC | 14.89 | 158.60B | ||
| GILD | GILEAD SCIENCES INC | 22.41 | 128.75B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1562.76 | 116.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 72.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.82B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.80B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.1 | 19.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.28 | 16.55B |
Related stock screener links
About PSTX
Company Profile
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2020-07-10. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Company Info
POSEIDA THERAPEUTICS INC
9390 Towne Centre Drive, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Eric Ostertag
Employees: 337
Company Website: https://poseida.com/
Investor Relations: https://investors.poseida.com/
Phone: 18587793100
PSTX FAQ
What is the stock price of PSTX?
The current stock price of PSTX is 9.5 USD.
What is the symbol for POSEIDA THERAPEUTICS INC stock?
The exchange symbol of POSEIDA THERAPEUTICS INC is PSTX and it is listed on the Nasdaq exchange.
On which exchange is PSTX stock listed?
PSTX stock is listed on the Nasdaq exchange.
Is PSTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PSTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PSTX.
Does PSTX stock pay dividends?
PSTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of PSTX?
PSTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
PSTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PSTX. When comparing the yearly performance of all stocks, PSTX is one of the better performing stocks in the market, outperforming 98.96% of all stocks.
PSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PSTX. PSTX may be in some trouble as it scores bad on both profitability and health.
PSTX Financial Highlights
Over the last trailing twelve months PSTX reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 58.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.7% | ||
| ROE | -69.67% | ||
| Debt/Equity | 0.68 |
PSTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 50% to PSTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 30.29% and a revenue growth 217.39% for PSTX